Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation

Do-Kyun Kim, Geethani Bandara, Young-Eun Cho, Hirsh D. Komarow, Danielle R. Donahue, Baktiar Karim, Moon-Chang Baek, Ho Min Kim, Dean D. Metcalfe and Ana Olivera ()
Additional contact information
Do-Kyun Kim: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
Geethani Bandara: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
Young-Eun Cho: National Institute on Alcohol Abuse and Alcoholism, NIH
Hirsh D. Komarow: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
Danielle R. Donahue: National Institute of Neurological Disorders and Stroke, NIH
Baktiar Karim: National Cancer Institute, NIH
Moon-Chang Baek: Kyungpook National University
Ho Min Kim: Institute for Basic Science (IBS)
Dean D. Metcalfe: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
Ana Olivera: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)

Nature Communications, 2021, vol. 12, issue 1, 1-18

Abstract: Abstract Osteoporosis and other manifestations of bone disease are frequent in patients with systemic mastocytosis (SM) in association with the presence of mast cell infiltrates in bone marrow, although the mechanisms behind bone disease remain poorly understood. We find that extracellular vesicles (EVs) released by neoplastic mast cells and present in the serum of patients with SM (SM-EVs) block osteoblast differentiation and mineralization in culture, and when injected into mice diminish the expression of osteoblast markers, and trabecular bone volume and microarchitecture. We demonstrate that miRNA-30a and miRNA-23a, increased in SM-EVs and neoplastic mast cell-derived EVs, attenuate osteoblast maturation by suppressing expression of RUNX2 and SMAD1/5, essential drivers of osteogenesis. Thus, SM-EVs carry and deliver miRNAs that epigenetically interfere with bone formation and can contribute to bone mass reduction in SM. These findings also suggest possibilities for novel approaches to the management of bone disease in mast cell proliferative disorders.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22754-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22754-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22754-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().